Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Thrombocytosis 1Sarcoma, Ewing 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasms, Neuroepithelial 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

Carboplatin 4Pemetrexed 3pembrolizumab 2patritumab 2osimertinib 2Sunitinib 2Standard of Care 2Paclitaxel 2Irinotecan 2Cisplatin 2Ascorbic Acid 2valrubicin 1pralsetinib 1palbociclib 1napabucasin 1linifanib 1genexol-PM 1dostarlimab 1alectinib 1Watchful Waiting 1Sorafenib 1Ramucirumab 1Patient Reported Outcome Measures 1Mitomycin 1KRN-330 1Interleukin-2 1Indocyanine Green 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms by Site × palbociclib × Clear all
NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NiKang Therapeutics, Inc.

Phase 2 Terminated
18 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡